|
|
název v anglickém jazyce není uveden
Michalská, Dana ; Štěpán, Jan (advisor) ; Stárka, Luboslav (referee) ; Pavelka, Karel (referee)
Microdamage of bone tissue is one of important aspects of quality of bone. Marked suppression of bone turnover by bisphosphonates is associated with increased accumulation of bone microdamage in animal models. The purpose of our study was to test the hypothesis that long-term treatment with alendronate (ALN) results in accumulation of microdamage in bone in women after menopause and in that case to impairment of bone quality. In this cross-sectional study, 66 women with postmenopausal osteoporosis (mean age of 68.0 years, mean BMD T-score of - 1.7 at total hip and -2.8 at lumbar spine; 62% with prevalent fractures) were evaluated. Thirtyeight had been treated previously with ALN (10 mg/day for a mean duration of 63.6 months) while 28 were treatment naive (TN). Before initiation of ALN treatment, mean serum PINP, plasma CTX, and OC were significantly increased as compared with reference values in premenopausal women (P< 0.05). After 6 months of ALN treatment, the mean of biochemical bone markers indicated significant suppression of bone remodeling (-70.5%, -84.1%, and - 67.3% for PINP, CTX and OC, respectively; P< 0.05). After 43 months of ALN treatment, markers of degradation and synthesis of type 1 collagen were below the lower limit of normal reference range in 50% of women treated with ALN. Without...
|
guest ::
